Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 15;7(11):11864-80.
doi: 10.18632/oncotarget.7689.

Severe chronic cerebral hypoperfusion induces microglial dysfunction leading to memory loss in APPswe/PS1 mice

Affiliations

Severe chronic cerebral hypoperfusion induces microglial dysfunction leading to memory loss in APPswe/PS1 mice

Maude Bordeleau et al. Oncotarget. .

Abstract

Cerebral vasculature plays a key role in controlling brain homeostasis. Cerebral vasculature dysfunction, associated to irregularities in cerebral blood perfusion, has been proposed to directly contribute to Alzheimer's disease (AD) pathogenesis. More precisely, chronic cerebral hypoperfusion, which impairs brain homeostasis, was demonstrated to take place even before cognitive decline. However, the mechanisms underlying the implication of chronic cerebral hypoperfusion in AD pathogenesis remain elusive. Therefore, this study aims at investigating the role of severe chronic cerebral hypoperfusion (SCCH) in AD pathogenesis. For this purpose, SCCH was induced in young APPswe/PS1 in order to evaluate the progression of AD-like pathology in these mice. We observed that SCCH accelerated the cognitive decline of young APPswe/PS1 mice, which was associated with an increased amyloid plaque number in brain parenchyma. In addition, SCCH reduced the activity of extracellular signal-regulated kinases 1/2 (ERK1/2), which has been shown to play an important role in the adaptive responses of neurons. Importantly, SCCH impaired the function of microglial cells, which are implicated in amyloid-β (Aβ) elimination. In vitro approaches underlined the ability of a low-glucose microenvironment to decrease the general activity and phagocytic capacity of microglia. By using a new model of SCCH, our study unravels new insights into the implication of severe chronic cerebral hypoperfusion in AD pathogenesis, mainly by altering microglial cell activity and consequently Aβ clearance.

Keywords: Alzheimer’s disease; Gerotarget; cerebral hypoperfusion; microglia.

PubMed Disclaimer

Figures

Figure 1
Figure 1. SCCH aggravates APPswe/PS1 cognitive deficits
The surgery has no effect on animal weight A.. Old APPswe/PS1 mice were used as positive control for cognitive decline. Water t-maze B.,C. and novel object recognition tests D. were used to assess mouse cognitive function. SCCH slightly increases the number of trails B. and significantly increases the latency C. of mice in the water t-maze test, which were comparable to those of old mice. SCCH significantly reduces mouse capacity in recognizing the novel object during the NOR test, which also were comparable to those of old mice. Data are means ± SEM (n = 6-8 animals per group) * P < 0.05 compared to sham group; #P < 0.05 compared with sham object 1. Pre-op: Pre-operatory.
Figure 2
Figure 2. Number of Aβ plaques increases following SCCH without affecting soluble Aβ levels
Aβ plaque number and size, and soluble Aβ peptide levels in the brain of APPswe/PS1 were assessed by immunofluorescence staining A.-C. and ELISA (D., E.), respectively. SCCH increases the number of Aβ plaques in the brain of mice A.,B. without affecting plaque load C.. The levels of soluble Aβ1-40 D. and soluble Aβ1-42 E. are not affected by SCCH. Data are means ± SEM (n = 6-8 animals per group, 3 sections per animal's brain for immunofluorescence staining) *** P < 0.005 compared with sham. Images were acquired with a 4X objective. Scale bar = 500μm.
Figure 3
Figure 3. SCCH induces slightly increases patrolling monocyte subset frequency in blood circulation
Frequency of total A., inflammatory C. and patrolling monocytes D. were analyzed by flow cytometry in blood. Using a gating strategy based on Ly6C expression level B., inflammatory and patrolling monocyte subsets were discriminated. SCCH does not affect the frequency of total monocyte frequency A. and inflammatory monocyte subset (Ly6CHigh) C., in the blood of mice 14 weeks following surgery. SCCH slightly (P = 0.0779) increases the frequency of patrolling monocyte subset (Ly6CLow) in the blood of mice D.. Data are means ± SEM (n = 6-8 animals per group). Data were analyzed with standard two-tailed unpaired t- test's.
Figure 4
Figure 4. SCCH alters microglial cell function in APPswe/PS1
Microglial cell function was assessed by using immunofluorescence staining A.-E.. SCCH significantly decreases microglial coverage (Iba+) of Aβ plaques A., B., without affecting overall microglial activation (CD68+) A., C.. SCCH significantly decreases the number of activated microglia associated to Aβ plaques D., and slightly decreases (P = 0.0559) the area of Aβ plaques covered by activated microglia E.. Data are means ± SEM (n = 6-8 animals per group, 3 section per animal's brain for immunofluorescence staining). * P < 0.05, ** P < 0.01 compared with sham group. Images were acquired with 4X objective. Scale bar = 500μm.
Figure 5
Figure 5. Low-glucose microenvironment alters microglial cell activity and phagocytic capacity
Viability, global microglial cell activity and phagocytic capacity were investigated by using, XTT assay A., Griess assay B. and flow cytometry C., D., respectively. Low-glucose microenvironment (i.e. DMEM-Low), maintained for 24 hours, does not alter BV2 cell (i.e. immortalized murine microglial cell) viability A.. BV2 cells exposed for 24 hours to 750 μM of H2O2 were used as a positive control for cell death A.. Low-glucose medium (i.e. DMEM-Low) significantly decreases global microglial cell activity B., activation C. and phagocytic capacity D.. BV2 cells incubated on ice were used as negative control for the phagocytosis assay D.. DMEM-High (4500mg/L glucose) and DMEM-Low (1000mg/L glucose) medium were used. Data are means ± S.D. (n = 5 experiments per condition, 4 replicates per experiment for viability assay; n = 6 experiments per condition, 3 replicates per experiment for Griess assay; n = 5-6 samples per condition for flow cytometry). * P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.0001 compared with DMEM High group; #### P < 0.0001 compared with control.
Figure 6
Figure 6. SCCH decreases ERK1/2 pathway activation
Western blot analysis was used to assess total A. and phosphorylated B. ERK1/2, which were corrected with β-actin expression level. SCCH does not affect total ERK1/2 expression A., but decreases ERK1/2 phosphorylation (i.e. activation) B.. Data are means ± SEM (n = 5-7 animals per group). * P < 0.05 compared with sham.

Similar articles

Cited by

References

    1. Wimo A, Jonsson L, Winbald B. An estimate of the worldwide prevalence and direct loss costs of dementia in 2003. Dement Geriatr Cogn Disord. 2006;21:175–181. - PubMed
    1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An english translation of Alzheimer's 1907 paper, ‘Uber eine eigenartige erkankaung der hirnrinde’. Clin Anat. 1995;8:429–431. - PubMed
    1. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke. 2003;34:335–337. - PubMed
    1. Knopman DS, Roberts R. Vascular risk factors: Imaging and Neuropathologic correlates. J Alzheimers Dis. 2010;20:699–709. - PMC - PubMed
    1. Marchesi VT. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: Implication for early detection and therapy. FASEB J. 2011;25:5–13. - PubMed

MeSH terms

Substances